Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.

Computational modeling continues to play an important role in novel therapeutics discovery and development. In this study, we have investigated the use of in silico approaches to develop inhibitors of the pleckstrin homology (PH) domain of AKT (protein kinase B). Various docking/scoring schemes have been evaluated, and the best combination was selected to study the system. Using this strategy, two hits were identified and their binding behaviors were investigated. Robust and predictive QSAR models were built using the k nearest neighbor (kNN) method to study their cellular permeability. Based on our in silico results, long flexible aliphatic tails were proposed to improve the Caco-2 penetration without affecting the binding mode. The modifications enhanced the AKT inhibitory activity of the compounds in cell-based assays, and increased their activity as in vivo antitumor testing.

[1]  D. V. van Aalten,et al.  Novel inositol phospholipid headgroup surrogate crystallized in the pleckstrin homology domain of protein kinase Balpha. , 2007, ACS chemical biology.

[2]  Lei Du-Cuny,et al.  In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. , 2009, Cancer research.

[3]  Nathan A. Baker,et al.  PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations , 2004, Nucleic Acids Res..

[4]  A. Tropsha,et al.  Development of quantitative structure-binding affinity relationship models based on novel geometrical chemical descriptors of the protein-ligand interfaces. , 2006, Journal of medicinal chemistry.

[5]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[6]  Maria Deak,et al.  High-Resolution Structure of the Pleckstrin Homology Domain of Protein Kinase B/Akt Bound to Phosphatidylinositol (3,4,5)-Trisphosphate , 2002, Current Biology.

[7]  G. Powis,et al.  D-3-Deoxy-3-substitutedmyo-inositol analogues as inhibitors of cell growth , 1991, Cancer Chemotherapy and Pharmacology.

[8]  P. Artursson.  Cell cultures as models for drug absorption across the intestinal mucosa. , 1991, Critical reviews in therapeutic drug carrier systems.

[9]  Lei Du-Cuny,et al.  Discovery of a novel class of AKT pleckstrin homology domain inhibitors , 2008, Molecular Cancer Therapeutics.

[10]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery. 5. Correlation of Caco-2 Permeation with Simple Molecular Properties , 2004, J. Chem. Inf. Model..

[11]  Chad L. Stoner,et al.  Pharmacokinetics and ADME optimization in drug discovery , 2008 .

[12]  Mats Kihlén,et al.  A General Model for Prediction of Caco‐2 Cell Permeability , 2004 .

[13]  G. Cruciani,et al.  MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.

[14]  D. Barford,et al.  Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. , 2002, Molecular cell.

[15]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[16]  M. Lemmon,et al.  Membrane recognition by phospholipid-binding domains , 2008, Nature Reviews Molecular Cell Biology.

[17]  P. Dennis,et al.  Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. , 2003, Journal of the American Chemical Society.

[18]  J. Testa,et al.  A Portrait of AKT Kinases: Human Cancer and Animal Models Depict a Family with Strong Individualities , 2004, Cancer biology & therapy.

[19]  Bernard Pirard,et al.  The Discovery of Kv1.5 Blockers as a Case Study for the Application of Virtual Screening Approaches , 2005, J. Chem. Inf. Model..

[20]  E. Meuillet,et al.  Chemoprevention of prostate cancer with selenium: An update on current clinical trials and preclinical findings , 2004, Journal of cellular biochemistry.

[21]  M. Lemmon,et al.  Pleckstrin homology domains and the cytoskeleton , 2002, FEBS letters.

[22]  G. Powis,et al.  Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. , 2003, Molecular cancer therapeutics.

[23]  Alexander Golbraikh,et al.  A Novel Automated Lazy Learning QSAR (ALL-QSAR) Approach: Method Development, Applications, and Virtual Screening of Chemical Databases Using Validated ALL-QSAR Models , 2006, J. Chem. Inf. Model..

[24]  Alexander Tropsha,et al.  Chemometric Analysis of Ligand Receptor Complementarity: Identifying Complementary Ligands Based on Receptor Information (CoLiBRI) , 2006, J. Chem. Inf. Model..

[25]  D. Rognan,et al.  Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.

[26]  Lei Du-Cuny,et al.  Development and evaluation of a new statistical model for structure-based high-throughput virtual screening , 2009, Int. J. Bioinform. Res. Appl..

[27]  Alexander Tropsha,et al.  Novel Variable Selection Quantitative Structure-Property Relationship Approach Based on the k-Nearest-Neighbor Principle , 2000, J. Chem. Inf. Comput. Sci..

[28]  N. C. Price,et al.  Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. , 2003, The Biochemical journal.

[29]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[30]  Jörg Huwyler,et al.  Computational aqueous solubility prediction for drug-like compounds in congeneric series. , 2008, European journal of medicinal chemistry.

[31]  Haruki Nakamura,et al.  The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive of PDB data , 2006, Nucleic Acids Res..

[32]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[33]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[34]  Huan Yang,et al.  The Akt/PKB pathway: molecular target for cancer drug discovery , 2005, Oncogene.

[35]  C. Kumar,et al.  AKT crystal structure and AKT-specific inhibitors , 2005, Oncogene.

[36]  Tamar Geiger,et al.  Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. , 2002, Biochemistry.

[37]  R. Huber,et al.  Structure-based optimization of novel azepane derivatives as PKB inhibitors. , 2004, Journal of medicinal chemistry.

[38]  D. Lambright,et al.  Membrane and juxtamembrane targeting by PH and PTB domains. , 2006, Biochimica et biophysica acta.

[39]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[40]  Sean Ekins,et al.  Three-Dimensional Quantitative Structure-Permeability Relationship Analysis for a Series of Inhibitors of Rhinovirus Replication , 2001, J. Chem. Inf. Comput. Sci..

[41]  Alexander Tropsha,et al.  Antitumor Agents 252. Application of validated QSAR models to database mining: discovery of novel tylophorine derivatives as potential anticancer agents , 2007, J. Comput. Aided Mol. Des..

[42]  Alexander Golbraikh,et al.  Rational selection of training and test sets for the development of validated QSAR models , 2003, J. Comput. Aided Mol. Des..

[43]  F. Lee,et al.  Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL , 2008, Cancer Chemotherapy and Pharmacology.

[44]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[45]  Ajay N. Jain.  Bias, reporting, and sharing: computational evaluations of docking methods , 2008, J. Comput. Aided Mol. Des..

[46]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[47]  Jaques Reifman,et al.  DOVIS: an implementation for high-throughput virtual screening using AutoDock , 2008, BMC Bioinformatics.

[48]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[49]  B. Lum,et al.  The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition , 2007, European Journal of Clinical Pharmacology.